| Literature DB >> 27003440 |
Sudhir Kumar1, Birgit Rathkolb1, Elisabeth Kemter1, Sibylle Sabrautzki2,3, Dian Michel2, Thure Adler2,4, Lore Becker2, Johannes Beckers2,3,5, Dirk H Busch4, Lillian Garrett6, Wolfgang Hans2,3, Sabine M Hölter6, Marion Horsch2, Martin Klingenspor7, Thomas Klopstock8,9, Ildikó Rácz10, Jan Rozman2,3,7, Ingrid Liliana Vargas Panesso2,8,9, Alexandra Vernaleken2,8, Andreas Zimmer10, Helmut Fuchs2,3, Valérie Gailus-Durner2,3, Martin Hrabě de Angelis2,3,5,9, Eckhard Wolf1, Bernhard Aigner1.
Abstract
Increased levels of blood plasma urea were used as phenotypic parameter for establishing novel mouse models for kidney diseases on the genetic background of C3H inbred mice in the phenotype-driven Munich ENU mouse mutagenesis project. The phenotypically recessive mutant line HST011 was established and further analyzed. The causative mutation was detected in the POU domain, class 3 transcription factor 3 (Pou3f3) gene, which leads to the amino acid exchange Pou3f3L423P thereby affecting the conserved homeobox domain of the protein. Pou3f3 homozygous knockout mice are published and show perinatal death. Line Pou3f3L423P is a viable mouse model harboring a homozygous Pou3f3 mutation. Standardized, systemic phenotypic analysis of homozygous mutants was carried out in the German Mouse Clinic. Main phenotypic changes were low body weight and a state of low energy stores, kidney dysfunction and secondary effects thereof including low bone mineralization, multiple behavioral and neurological defects including locomotor, vestibular, auditory and nociceptive impairments, as well as multiple subtle changes in immunological parameters. Genome-wide transcriptome profiling analysis of kidney and brain of Pou3f3L423P homozygous mutants identified significantly regulated genes as compared to wild-type controls.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27003440 PMCID: PMC4803225 DOI: 10.1371/journal.pone.0150472
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Analysis of Pou3f3 in wild-type and Pou3f3 mutant mice.
(A) Electropherogram of the Pou3f3 mutation. The box shows the T→C point mutation at nt 1268 (ENSMUST00000054883) from the wild-type codon leucine (L) to the mutant codon proline (P) at amino acid position 423. (B) Genotyping of mice by allele-specific PCR-RFLP reaction. SmlI restriction digest of the 460 bp PCR product results in 353 bp and 107 bp fragments of the wild-type allele. Hom, Pou3f3 homozygous mutant; Het, Pou3f3 heterozygous mutant; Wt, wild-type; M, pUC Mix 8 marker, MBI Fermentas. (C) Partial protein sequence alignment of the homeobox domain of murine POU3F3 with other species. The underlined amino acid residue shows the position of the Pou3f3 mutation.
Fig 2Immunohistochemical localization of POU3F3 in kidneys.
POU3F3 was detected in nuclei of numerous but not all tubule segments with weak up to strong staining intensity in a wild-type kidney. The immunostaining pattern and staining intensity of POU3F3 in the kidney of a Pou3f3 homozygous mutant mouse was similar to the findings observed in the wild-type control kidney. DAB (brown color); nuclear staining: haemalum (blue color). Age of mice analyzed: 22 months. Bars represent 100 μm.
Open field behavioral analysis of line Pou3f3.
| Males | Females | Genotype: | |||
|---|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| Distance traveled–total (cm) | 11382 ± 5683 | 8013 ± 2754 | 12443 ± 5374 | 9987 ± 3127 | a |
| Number of rearings—total | 6.7 ± 11.0 | 16.4 ± 23.9 | 2.3 ± 6.6 | 47.9 ± 45.3 | c |
| Percent distance in the center—total | 18.3 ± 13.0 | 5.1 ± 5.7 | 20.3 ± 11.1 | 9.9 ± 7.0 | c |
| Percent time spent in the center—total | 15.0 ± 10.9 | 3.5 ± 3.8 | 16.7 ± 9.6 | 7.0 ± 4.9 | c |
| Whole arena—resting time (sec) | 11.1 ± 15.1 | 24.6 ± 33.8 | 3.3 ± 4.9 | 68.5 ± 62.6 | c |
| Whole arena—average speed (cm/sec) | 9.6 ± 4.9 | 6.9 ± 2.6 | 10.4 ± 4.5 | 8.9 ± 3.1 | a |
| Latency to enter in the center (sec) | 37 ± 59 | 203 ± 347 | 89 ± 133 | 115 ± 129 | |
| Number of entries in the center | 131 ± 123 | 26 ± 30 | 142 ± 92 | 54 ± 38 | c |
8-week-old mice were tested in the open field for 20 min. No. per genotype and sex: n = 12–16. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a, P < 0.05; c, P < 0.001.
Neurology analysis by modified SHIRPA of line Pou3f3.
| Males | Females | Genotype: | |||
|---|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| Body weight (g) | 22.4 ± 1.7 | 27.7 ± 2.2 | 18.9 ± 1.8 | 24.9 ± 2.8 | c |
| Locomotor activity (floor squares crossed) | 11.1 ± 10.2 | 7.4 ± 5.8 | 10.8 ± 7.9 | 16.4 ± 7.1 | |
| Lacrimation | 5 of 14 | 0 of 16 | 6 of 12 | 0 of 16 | c |
| Pelvic elevation (more than 5) | 4 of 14 | 0 of 16 | 3 of 12 | 0 of 16 | b |
| Tail elevation: horizontal extension | 4 of 14 | 0 of 16 | 5 of 12 | 4 of 16 | 0.06 |
| Trunk curl: present | 8 of 14 | 3 of 16 | 9 of 12 | 4 of 16 | b |
| Urination: absent | 12 of 14 | 7 of 16 | 6 of 12 | 7 of 16 | 0.07 |
| Contact righting reflex: absent | 11 of 14 | 2 of 16 | 8 of 12 | 1 of 16 | c |
8-week-old mice were tested. No. per genotype and sex: n = 12–16. Data are presented as mean ± standard deviation (body weight, locomotor activity) and as exact numbers. Significance vs. wild-type controls: b, P < 0.01; c, P < 0.001.
Additional locomotor analysis requiring balance maintenance of line Pou3f3.
| Males | Females | Genotype: | ||||
|---|---|---|---|---|---|---|
| Test | Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| Balance beam | Square, Ø 20 mm (sec) | 28.8 ± 8.4 | 14.0 ± 7.7 | 24.5 ± 8.8 | 10.8 ± 4.8 | c |
| Square, Ø 12 mm (sec) | 25.6 ± 8.5 | 13.5 ± 7.7 | 24.0 ± 12.2 | 12.1 ± 5.5 | c | |
| Round, Ø 22 mm (sec) | 22.2 ± 8.2 | 10.6 ± 5.3 | 18.6 ± 6.2 | 9.7 ± 5.4 | c | |
| Round, Ø 15 mm (sec) | 23.1 ± 8.4 | 14.6 ± 7.5 | 21.3 ± 9.7 | 15.0 ± 7.7 | b | |
| Beam ladder | Time (sec) | 22.6 ± 4.4 | 17.8 ± 6.1 | 23.1 ± 3.8 | 17.1 ± 4.4 | c |
| Fore paw slips (n) | 0.5 ± 0.5 | 0.3 ± 0.5 | 0.4 ± 0.4 | 0.2 ± 0.2 | a | |
| Hind paw slips (n) | 6.6 ± 2.3 | 3.4 ± 1.5 | 5.1 ± 1.8 | 2.4 ± 1.7 | c | |
| Stops (n) | 4.2 ± 1.1 | 3.3 ± 1.5 | 4.1 ± 0.9 | 2.9 ± 1.0 | b | |
| Swim ability | Normal (%) | 46 | 100 | 10 | 93 | c |
| Irregular (%) | 54 | 0 | 90 | 7 | c |
Analysis was done at the age of 19 weeks. No. per genotype and sex: n = 10–16. Data are presented as mean ± standard deviation (balance beam, beam ladder). For the swim ability test, the percentages of the mice are shown. Significance vs. wild-type controls: a, P < 0.05; b, P < 0.01; c, P < 0.001.
Fig 3Morphological analysis of the inner ears of line Pou3f3.
Morphological analysis of the inner ears using the whole mount clearing method showed abnormal superior semi-circular canal formation in the homozygous mutants of line Pou3f3. Left picture shows a control inner ear with normal semi-circular canals. Right picture shows the smaller inner ear of a Pou3f3 homozygous mutant animal with abnormal superior semi-circular canal formation. Red arrow shows the constriction of the superior semi-circular canal. SSCC: superior semi-circular canal, PSCC: posterior semi-circular canal, ASCC: anterior semi-circular canal.
Clinical chemical analysis of line Pou3f3.
| Males | Females | Genotype: | |||
|---|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| Na+ (mmol/l) | 153 ± 1 | 153 ± 1 | 151 ± 3 | 150 ± 4 | |
| K+ (mmol/l) | 5.1 ± 0.4 | 4.6 ± 0.3 | 4.7 ± 0.3 | 3.9 ± 0.3 | c |
| Ca2+ (mmol/l) | 2.4 ± 0.1 | 2.5 ± 0.1 | 2.5 ± 0.1 | 2.4 ± 0.1 | |
| Cl- (mmol/l) | 109 ± 1 | 108 ± 2 | 112 ± 3 | 110 ± 3 | b |
| Fe (μmol/l) | 38.0 ± 3.4 | 36.8 ± 3.8 | 40.5 ± 8.8 | 37.6 ± 3.8 | |
| Pi (mmol/l) | 1.5 ± 0.3 | 1.5 ± 0.2 | 1.7 ± 0.3 | 2 ± 0.4 | |
| Total protein (g/l) | 53.2 ± 1.4 | 56.1 ± 1.8 | 52.7 ± 1.3 | 53.5 ± 2.4 | c |
| Albumin (g/l) | 29.7 ± 3.4 | 31.5 ± 1 | 30.5 ± 2.5 | 32 ± 1.6 | b |
| Creatinine (μmol/l) | 16.5 ± 1.3 | 15.9 ± 1.0 | 16.5 ± 2.8 | 11.1 ± 2.4 | c |
| Urea (mmol/l) | 20.8 ± 1.8 | 10.7 ± 0.9 | 18.7 ± 2.1 | 8.7 ± 1.3 | c |
| Cholesterol (mmol/l) | 3.5 ± 0.2 | 4.3 ± 0.4 | 3.1 ± 0.2 | 3.3 ± 0.4 | c |
| Triglycerides (mmol/l) | 2.2 ± 0.6 | 3.4 ± 0.8 | 2.1 ± 0.6 | 3.0 ± 1.0 | c |
| ALT (U/l) | 45 ± 50 | 33 ± 7 | 27 ± 5 | 28 ± 6 | |
| AST (U/l) | 72 ± 30 | 51 ± 8 | 72 ± 22 | 48 ± 7 | c |
| AP (U/l) | 132 ± 14 | 111 ± 9 | 148 ± 25 | 132 ± 14 | c |
| α-Amylase (U/l) | 717 ± 86 | 726 ± 55 | 694 ± 59 | 623 ± 59 | |
| Glucose (mmol/l) | 9.4 ± 1.8 | 10.6 ± 2.2 | 10.4 ± 2.0 | 11.5 ± 1.8 | a |
| LDH (U/l) | 250 ± 104 | 178 ± 38 | 239 ± 53 | 181 ± 39 | c |
Creatinine, plasma creatinine analyzed by the enzymatic method; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; LDH, lactate dehydrogenase.
15-week-old mice were tested. No. per genotype and sex: n = 13–16. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a, P < 0.05; b, P < 0.01; c, P < 0.001.
Hematological analysis of line Pou3f3.
| Males | Females | Genotype: | |||
|---|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| WBC (103/μl) | 8.7 ± 1.5 | 7.4 ± 1.3 | 8.7 ± 2.2 | 7.1 ± 1.4 | b |
| RBC (106/μl) | 8.9 ± 0.3 | 9.5 ± 0.6 | 9.2 ± 0.3 | 9.6 ± 0.3 | c |
| PLT (103/μl) | 972 ± 74 | 1093 ± 107 | 1006 ± 111 | 1168 ± 93 | c |
| HGB (g/dl) | 14.5 ± 0.5 | 15.6 ± 0.9 | 15.1 ± 0.5 | 16.0 ± 0.4 | c |
| HCT (%) | 50.2 ± 1.7 | 54.0 ± 3.3 | 52.5 ± 1.5 | 55.6 ± 1.5 | c |
| MCV (fl) | 56.2 ± 0.4 | 56.9 ± 0.7 | 57.0 ± 0.6 | 57.8 ± 0.7 | c |
| MCH (pg) | 16.2 ± 0.3 | 16.5 ± 0.4 | 16.4 ± 0.4 | 16.6 ± 0.2 | a |
| MCHC (g/dl) | 28.8 ± 0.4 | 28.9 ± 0.6 | 28.8 ± 0.6 | 28.8 ± 0.4 |
WBC, white blood cell count; RBC, red blood cell count; PLT, platelet count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration.
15-week-old mice were tested. No. per genotype and sex: n = 13–16. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a, P < 0.05; b, P < 0.01; c, P < 0.001.
Urine analysis of line Pou3f3 (in an additional group of mice not transferred to the German Mouse Clinic).
| Males | Females | |||
|---|---|---|---|---|
| Parameter | Homozygous mutant | Controls | Homozygous mutant | Controls |
| Body weight (g) | 20.4 ± 1.4 c | 26.3 ± 3.6 | 18.2 ± 2.2 b | 23.3 ± 2.7 |
| Water | ||||
| Water intake (ml/day) | 5.9 ± 3.0 | 4.3 ± 0.7 | 5.5 ± 1.7 | 4.9 ± 2.3 |
| Food intake (g/day) | 3.5 ± 1.2 | 3.9 ± 0.6 | 3.6 ± 0.7 | 4.2 ± 0.7 |
| Urine volume (ml/day) | 1.5 ± 0.7 a | 0.9 ± 0.3 | 1.6 ± 0.5 | 1.0 ± 0.6 |
| Na+ (μmol/day) | 125 ± 47 | 169 ± 36 | 170 ± 69 | 231 ± 67 |
| K+ (μmol/day) | 375 ± 114 | 422 ± 149 | 505 ± 117 | 600 ± 232 |
| Ca2+ (μmol/day) | 1.5 ± 0.5 | 1.4 ± 0.6 | 3.0 ± 0.8 | 2.0 ± 0.9 |
| Cl- (μmol/day) | 217 ± 78 | 274 ± 73 | 315 ± 112 | 395 ± 118 |
| Mg2+ (μmol/day) | 9 ± 7 | 15 ± 9 | 23 ± 13 | 22 ± 9 |
| Pi (μmol/day) | 50 ± 54 | 63 ± 47 | 77 ± 71 | 99 ± 59 |
| Creatinine-J (μmol/day) | 3.5 ± 1.0 | 4.0 ± 1.0 | 3.8 ± 1.1 | 4.9 ± 1.3 |
| Creatinine-E (μmol/day) | 2.1 ± 0.5 | 2.5 ± 0.6 | 2.5 ± 0.7 | 3.1 ± 0.9 |
| Urea (mmol/day) | 1.2 ± 0.3 | 1.3 ± 0.4 | 1.6 ± 0.4 | 1.8 ± 0.6 |
| Uric acid (nmol/day) | 329 ± 94 b | 587 ± 154 | 522 ± 84 b | 977 ± 208 |
| Glucose (μmol/day) | 1.5 ± 1.1 | 2.1 ± 1.1 | 5.0 ± 2.5 a | 3.1 ± 0.8 |
| Total protein (mg/day) | 5.0 ± 1.7 | 7.3 ± 3.7 | 0.9 ± 0.3 | 2.9 ± 2.1 |
| Albumin (nmol/day) | 1.4 ± 0.3 | 1.9 ± 0.6 | 2.0 ± 0.2 | 2.2 ± 0.7 |
| Deprivation of water for 24 h | ||||
| Loss of body weight (%) | 13.2 ± 2.2 b | 9.6 ± 1.4 | 13.4 ± 1.2 c | 9.7 ± 1.3 |
| Food intake (g/day) | 1.2 ± 0.4 c | 2.3 ± 0.3 | 1.8 ± 0.2 b | 2.3 ± 0.3 |
| Urine volume (ml/day) | 0.6 ± 0.3 | 0.5 ± 0.2 | 0.7 ± 0.1 | 0.5 ± 0.2 |
Creatinine-J, creatinine analyzed by Jaffe’s kinetic method; Creatinine-E, creatinine analyzed by the enzymatic method.
The analysis was done under basal conditions and after deprivation of drinking water for 24 h in metabolic cages. 14-15-week-old mice were tested. Heterozygous mutant and wild-type littermates were used as controls. No. per group and sex: n = 4–10. Data are presented as mean ± standard deviation. Student’s t-test vs. controls: a P < 0.05, b P < 0.01, c P < 0.001.
Dual energy X-ray absorption (DXA) analysis of bone- and weight-related parameters in line Pou3f3.
| Males | Females | |||
|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type |
| BMD (mg/cm2) | 54 ± 6 b | 63 ± 5 | 54 ± 5 | 61 ± 6 |
| BMC (mg) | 548 ± 79 c | 883 ± 246 | 522 ± 196 a | 804 ± 249 |
| Bone content (%) | 2.0 ± 0.3 a | 2.4 ± 0.6 | 2.0 ± 0.4 | 2.3 ± 0.4 |
| Body length (cm) | 9.9 ± 0.2 b | 10.3 ± 0.2 | 9.9 ± 0.4 a | 10.3 ± 0.4 |
| Body weight (g) | 28.1 ± 2.7 c | 36.3 ± 3.3 | 25.2 ± 4.8 c | 33.8 ± 6.3 |
| Fat mass (g) | 5.8 ± 1.8 c | 15.1 ± 5.5 | 6.6 ± 4.7 b | 14.7 ± 7.3 |
| Lean mass (g) | 16.0 ± 1.2 | 14.0 ± 4.0 | 12.9 ± 1.3 | 12.7 ± 3.2 |
BMD, bone mineral density; BMC, bone mineral content.
Analysis was done at the age of 19 weeks. No. per genotype and sex: n = 8–16. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a P < 0.05, b P < 0.01, c P < 0.001.
Analysis of energy metabolism in line Pou3f3.
| Males | Females | Genotype: | ||||
|---|---|---|---|---|---|---|
| Test | Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| Indirect calorimetry | Body weight (g) | 24.3 ± 1.3 | 30.7 ± 2.5 | 20.9 ± 2.1 | 28.4 ± 3.3 | c |
| Body temperature (°C) | 35.7 ± 0.7 | 36.2 ± 0.4 | 36.4 ± 0.3 | 36.8 ± 0.3 | b | |
| Food intake (g) | 2.8 ± 0.3 | 3.2 ± 0.8 | 2.8 ± 0.4 | 3.6 ± 0.6 | ||
| Average VO2 consumption (ml/h animal) | 85 ± 4 | 95 ± 6 | 81 ± 6 | 99 ± 7 | a | |
| Average RER (VCO2/VO2) | 0.89 ± 0.01 | 0.90 ± 0.04 | 0.90 ± 0.02 | 0.92 ± 0.03 | ||
| Adjusted mean MR (mW) | 507 ± 21 | 508 ± 21 | 515 ± 23 | 556 ± 50 | 0.05 | |
| Adjusted RMR (mW) | 375 ± 17 | 383 ± 23 | 392 ± 11 | 492 ± 24 | c | |
| Average distance (cm/20 min) | 843 ± 213 | 658 ± 86 | 958 ± 400 | 810 ± 298 | 0.06 | |
| Average rearings (counts/20 min) | 144 ± 59 | 119 ± 20 | 144 ± 71 | 149 ± 69 | ||
| TD-NMR | Body weight (g) | 24.8 ± 1.6 | 30.5 ± 2.6 | 20.1 ± 2.8 | 27.4 ± 3.2 | c |
| Fat mass (g) | 5.4 ± 0.6 | 7.8 ± 1.4 | 4.9 ± 1.1 | 8.0 ± 1.9 | ||
| Lean mass (g) | 15.8 ± 1 | 18.9 ± 1.3 | 12.2 ± 1.5 | 16.1 ± 1.5 | 0.06 |
RER, respiratory exchange ratio; adjusted mean MR, metabolic rate (MR) was adjusted for body mass by subtracting residual MR from modeled mean expected MR; adjusted RMR, adjusted resting metabolic rate (i.e. lowest MR during the measurement); TD-NMR, time domain nuclear magnetic resonance.
Analysis was done on 11-week-old mice under ad libitum conditions. No. per genotype and sex: n = 9–16. Substrate utilization rates during indirect calorimetry were calculated as described [27]. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a, P < 0.05; b, P < 0.01; c, P < 0.001.
Immunology analysis of line Pou3f3.
| Males | Females | Genotype: | |||
|---|---|---|---|---|---|
| Parameter | Homozygous mutant | Wild-type | Homozygous mutant | Wild-type | |
| CD45+/T cells | 33.9 ± 4.4 | 36.4 ± 3.2 | 36.6 ± 4.4 | 39.2 ± 5.2 | a |
| CD45+/CD3+CD4+ | 22.0 ± 3.1 | 23.5 ± 2.5 | 23.5 ± 2.8 | 25.1 ± 4.0 | 0.07 |
| CD45+/CD3+CD8+ | 8.9 ± 1.1 | 9.7 ± 1.0 | 10.2 ± 1.6 | 11.4 ± 1.2 | b |
| CD45+/B cells | 28.7 ± 3.5 | 28.7 ± 2.7 | 28.3 ± 5.0 | 33.1 ± 5.8 | a |
| CD45+/CD5-NK+ | 6.3 ± 1.4 | 6.9 ± 1.6 | 4.4 ± 1.0 | 5.7 ± 1.2 | b |
| CD45+/CD11b+Gr1+ | 28.6 ± 6.1 | 25.6 ± 3.7 | 28.0 ± 6.1 | 17.5 ± 5.7 | c |
| CD45+/NK-Gr1-CD11b+ | 2.2 ± 0.9 | 2.7 ± 0.6 | 2.3 ± 0.7 | 2.6 ± 1.4 | |
| CD45+/CD3+γδTCR+ | 0.99 ± 0.2 | 0.94 ± 0.3 | 0.99 ± 0.3 | 0.98 ± 0.3 | |
| CD45+/CD5+NK+ | 0.06 ± 0.05 | 0.05 ± 0.03 | 0.02 ± 0.01 | 0.02 ± 0.02 | |
| CD45+/CD3+CD4+CD25+ | 0.89 ± 0.17 | 0.89 ± 0.14 | 1.03 ± 0.25 | 0.94 ± 0.11 | |
| CD3+CD4+/CD25+ | 4.1 ± 0.6 | 3.8 ± 0.5 | 4.4 ± 1.2 | 3.8 ± 0.4 | a |
| CD3+CD4+/CD62L+ | 90.0 ± 3.9 | 91.3 ± 2.6 | 85.5 ± 8.5 | 86.2 ± 5.3 | |
| CD3+CD4+/CD44+ | 2.5 ± 0.4 | 2.0 ± 0.3 | 3.1 ± 0.7 | 2.3 ± 0.5 | c |
| CD3+CD8+/CD62L+ | 97.6 ± 1.0 | 97.5 ± 0.9 | 97.2 ± 1.7 | 97.4 ± 1.1 | |
| CD3+CD8+/CD44+ | 3.5 ± 0.9 | 3.3 ± 0.9 | 2.3 ± 0.8 | 1.6 ± 0.8 | a |
| B cells/IgD+ | 89.3 ± 2.8 | 88.1 ± 2.8 | 87.4 ± 2.9 | 86.6 ± 3.2 | |
| B cells/CD5+ | 5.3 ± 1.7 | 5.3 ± 1.0 | 5.2 ± 2.0 | 5.1 ± 1.5 | |
| B cells/ B220+MHCclassII+ | 97.9 ± 1.0 | 98.2 ± 0.6 | 93.6 ± 5.1 | 95.4 ± 3.1 | |
| NK+/CD11b+ | 9.5 ± 6.3 | 12.9 ± 6.5 | 3.4 ± 1.9 | 3.0 ± 2.4 | |
| CD3+ rest | 2.9 ± 0.5 | 3.1 ± 0.4 | 2.8 ± 0.7 | 2.7 ± 0.5 | |
| ratio CD4: CD8 | 2.5 ± 0.1 | 2.4 ± 0.2 | 2.3 ± 0.2 | 2.2 ± 0.2 | |
| ratio granulocytes: (T cells + B cells) | 0.46 ± 0.13 | 0.40 ± 0.07 | 0.44 ± 0.13 | 0.25 ± 0.10 | c |
| ratio T cells: B cells | 1.20 ± 0.24 | 1.28 ± 0.18 | 1.33 ± 0.29 | 1.22 ± 0.27 |
Data are frequencies of main leukocyte subpopulations in peripheral blood (%) measured by flow cytometry.
15-week-old mice were tested. No. per genotype and sex: n = 13–16. Data are presented as mean ± standard deviation. Significance vs. wild-type controls: a, P < 0.05; b, P < 0.01; c, P < 0.001.